

AT A GLANCE

04/08/2022

Coronavirus Disease 2019 (COVID-19)

Updated twice weekly on Tuesdays and Fridays, and current as of 3:00 p.m. on the date it was posted.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

Table of Contents

New Content	3
Public Health Agencies.....	3
Public Health Agency of Canada canada.ca	3
BC Centre for Disease Control bccdc.ca	3
Institut national de santé publique 	3
CDC: Centers for Disease Control and Prevention cdc.gov	4
ECDC: European Centre for Disease Prevention and Control ecdc.europa.eu	5
FDA: U.S. Food & Drug Administration fda.gov	6
Public Health England gov.uk.....	6
World Health Organization who.int	6
Other relevant government bodies / health care organizations	7
CIDRAP: Center for Infectious Disease Research Policy cidrap.umn.edu	10
National Collaborating Centre for Environmental Health ncceh.ca.....	10
Updated Daily.....	11
COVID-19 resources (case counts) arcgis.com.....	11
COVID-19 Canada Open Data Working Group COVID-19 CODWG	11
Johns Hopkins CCSE systems.jhu.edu.....	11
NextStrain nextstrain.org.....	11
Guidelines and Technical documents (updated weekly)	11
Section I: General Guidelines.....	11
Ontario / Canada Main Page	11
Reopening/Rebuilding Guidelines	11

Vaccinations- General	12
Vaccinations- Specific populations	17
Vaccinations- Adverse Effects	19
Background Information/Case Definitions.....	20
Laboratories.....	21
Miscellaneous Guidelines	23
Data & Surveillance	24
Variants – Omicron.....	25
Testing.....	26
Symptoms/Treatment.....	28
COVID-19 Diagnosis in Children	29
Post-COVID-19 Condition	30
Case Investigation & Contact Tracing	30
Infection Prevention and Control	32
Section II: Guidelines for Health Sectors.....	33
Healthcare Providers	33
First Responders, Dentistry, Pharmacy, and Allied Health	34
Death Services	34
Congregate Living (including Long-Term Care, Prisons, and Shelters)	35
Section III: Guidelines for the Community	37
Travel, Transport & Borders.....	37
Schools / Childcare	38
Mental Health /Addiction /Inequity.....	38
Community	39
Businesses/Workplaces	40
Masks (Non-Medical)	41

New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca

Instead of daily case counts and vaccinations, starting the week of December 6, 2021 we will be reporting weekly trends. For daily case counts, you can still check [2019 novel coronavirus: outbreak update](#), or [COVID-19 vaccination in Canada](#) for vaccination rates.

- [An Advisory Committee Statement \(ACS\) National Advisory Committee on Immunization \(NACI\): Initial guidance on a second booster dose of COVID-19 vaccines in Canada \[04-05-2022\]](#)
- [Statement from the Council of Chief Medical Officers of Health \(CCMOH\) on the importance of staying up to date with COVID-19 vaccines \[04-05-2022\]](#)
- [Vaccine coverage: This report was last updated on April 1, 2022 with data up to and including March 27, 2022.](#)
 - 85.49% of the population 5 years and older are fully vaccinated
- [Canada COVID-19 weekly epidemiology report: 20 March to 26 March 2022 \(week 12\) \[04-01-2022\]](#)
- [Mathematical modelling and COVID-19 \[updated regularly\]](#)
- [COVID-19 daily epidemiology update \[updated regularly\]](#)
- [COVID-19 data trends \[updated regularly\]](#)

BC Centre for Disease Control | bccdc.ca

- [PHO press briefing slides: COVID-19 April 5 update \[04-07-2022\]](#)
- [Antimicrobial and immunomodulatory therapy in adult patients with COVID-19 \[updated 04-05-2022\]](#)
- [COVID-19 protein subunit vaccine \(HealthLinkBC file #124c\) \[04-05-2022\]](#)
- [Immunization manual: summary of changes: admin circular \[04-05-2022\]](#)
 - [COVID-19 vaccine eligibility \[updated 04-05-2022\]](#)
 - [COVID-19 mRNA vaccine COMIRNATY® \(Pfizer\) \(adult/adolescent\) \[updated 04-05-2022\]](#)
 - [COVID-19 mRNA vaccine SPIKEVAX™ \(Moderna\) \[updated 04-05-2022\]](#)
 - [COVID-19 vaccine VAXZEVRIA™/COVISHIELD \(AstraZeneca/Verity Pharmaceuticals\) \[updated 04-05-2022\]](#)
 - [COVID-19 vaccine \(Ad26.COV2.S \[recombinant\]\) \(Janssen Inc.\) \[updated 04-05-2022\]](#)
 - [COVID-19 vaccine Nuvaxovid™ \(Novavax\) \[updated 04-05-2022\]](#)

Institut national de santé publique | inspq.qc.ca

- [Methodology for the Indigenous Health Research Monitoring Bulletin \[04-06-2022\]](#)
- [SRAS-CoV-2 - capsules vidéo sur les recommandations de PCI pour les milieux de soins \[04-06-2022\]](#)
- [Housing and social inequalities in health in times of COVID-19: strategies for promoting affordable quality housing \[04-05-2022\]](#)
- [Measures to reduce sedentary behaviour and encourage physical activity in persons 65 and older living at home during the COVID-19 pandemic \[04-05-2022\]](#)

- [Preventing violence and suicide within the context of the COVID-19 pandemic: courses of action \[04-05-2022\]](#)
- [Preventing loneliness in young adults in the context of a pandemic \[04-05-2022\]](#)
- [COVID-19: safe use of urban parks and green spaces during gradual lockdown lifting \[04-05-2022\]](#)
- [Pandémie, habitudes de vie, qualité du sommeil et préoccupation à l'égard du poids - résultats du 5 avril 2022 \[04-05-2022\]](#)
- [Pandémie et insécurité alimentaire - résultats du 5 avril 2022 \[04-05-2022\]](#)
- [Pandémie et vaccination - résultats du 5 avril 2022 \[04-05-2022\]](#)
- [Faits saillants du 5 avril 2022 - sondages sur les attitudes et comportements des adultes québécois \[04-05-2022\]](#)

CDC: Centers for Disease Control and Prevention | [cdc.gov](https://www.cdc.gov)

- [COVID data tracker weekly review: interpretive summary for April 8, 2022](#)
 - [As of April 6, 2022, 22.8 million children and adolescents ages 5–17 years have received their primary series of a COVID-19 vaccine and are considered fully vaccinated. Approximately 23.7% of fully vaccinated adolescents ages 12–17 years have also received a booster dose, which provides the best protection against severe COVID-19.* Recent studies show that vaccination continues to protect children and adolescents against emergency department/urgent care visits, hospitalizations, and death associated with the Omicron variant.](#)
 - Overall, about 255.9 million people, or 77.1% of the total U.S. population, have received at least one dose of vaccine. About 218.0 million people, or 65.7% of the total U.S. population, have been fully vaccinated.*
 - *Represents the number of people who have received the second dose in a two-dose COVID-19 vaccine series (such as the Pfizer-BioNTech or Moderna vaccines) or one dose of the single-shot Johnson & Johnson's Janssen vaccine.
 - New hospital admissions: As of April 6, 2022, the current 7-day moving average of daily new cases (26,596) increased 4.9% compared with the previous 7-day moving average (25,363). A total of 80,111,065 COVID-19 cases have been reported in the United States as of April 6, 2022.
 - The current 7-day daily average for March 30–April 5, 2022, was 1,406. This is a 10.3% decrease from the prior 7-day average (1,567) from March 23–29, 2022.
 - The current 7-day moving average of new deaths (497) has decreased 22.1% compared with the previous 7-day moving average (638). As of April 6, 2022, a total of 981,197 COVID-19 deaths have been reported in the United States.
- [EARLY RELEASE: COVID-19 mortality and vaccine coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022 \[04-08-2022\]](#)
- [Notes from the field: SARS-CoV-2 Omicron variant infection in 10 persons within 90 days of previous SARS-CoV-2 Delta variant infection — four states, October 2021–January 2022 \[04-07-2022\]](#)
- [Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination — PCORnet, United States, January 2021–January 2022 \[04-07-2022\]](#)
- [Cases in the U.S. \[04-07-2022\]](#)
- [Overall US COVID-19 vaccine distribution and administration update as of Thu, 07 Apr 2022 06:00:00 EST \[04-07-2022\]](#)
- [COVID-19 forecasts: deaths \[04-06-2022\]](#)

- [Previous COVID-19 forecasts: hospitalizations \[04-06-2022\]](#)
- [Interim considerations for health departments for SARS-CoV-2 testing in homeless shelters and encampments \[04-06-2022\]](#)
- [Tribal communities \[updated 04-05-2022\]](#)
- [Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community \[updated 04-04-2022\]](#)
- [Collection and submission of postmortem specimens from deceased persons with confirmed or suspected COVID-19 \[updated 04-04-2022\]](#)
- [Overview and methodology of the Adolescent Behaviors and Experiences Survey — United States, January–June 2021 \[04-01-2022\]](#)
- [Assessment of epidemiology capacity in state health departments — United States, 2021 \[04-01-2022\]](#)
- [Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S \(Janssen \[Johnson & Johnson\]\) vaccine dose against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults — VISION Network, 10 States, December 2021–March 2022 \[04-01-2022\]](#)
- [Use of COVID-19 vaccines in the United States: interim clinical considerations \[updated 03-30-2022\]](#)

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu

- [Communicable disease threats report, 3-9 April 2022, week 14 \[04-08-2022\]](#)
- [COVID-19 situation update worldwide, as of week 13, updated 7 April 2022 \[04-07-2022\]](#)
- [Country overview report: week 13 2022 \[04-07-2022\]](#)
 - “At the end of week 13, 2022 (week ending 3 April), the recent resurgence observed in the EU/EEA appeared to be slowing down, with signs that the sustained transmission recently observed among older populations may not translate into rates of severe disease as significant as those seen during the initial Omicron wave. This is despite the continued expansion of BA.2 and the widespread lifting of public health measures.
 - Fewer countries than last week reported increases in transmission among people aged 65 years and above, and only four countries reported increases in ICU indicators. However, the epidemiological situation remains fairly mixed, with some countries reporting concerning trends in indicators of severity. Transmission remains very high overall, and at record levels among the 65+ age group in four countries.
 - As of week 13, 2022, ECDC has discontinued the assessment of each country’s epidemiological situation using its composite score, mainly due to changes in testing strategies affecting the reliability of the indicators for all-age case rates and test positivity.
 - The overall COVID-19 case notification rate for the EU/EEA was 1 778 per 100 000 population (1 907 the previous week). This rate has been decreasing for one week. The 14-day COVID-19 death rate has been decreasing for one week (26.3 deaths per million population, compared with 30.4 deaths the previous week). Of 28 countries with data on hospital or ICU admissions or occupancy up to week 13, six reported an increasing trend in at least one of these indicators compared with the previous week.
 - [...] Compared with the previous week, decreasing trends in cases, stable trends in hospital admissions, and increasing trends in deaths are forecast for the EU/EEA overall by the end of week 15. Forecasts for individual countries may differ from those for the EU/EEA as a whole. Note that forecasts of cases are considered to be increasingly

unreliable due to changes in testing criteria and reporting procedures. All current forecasts, in particular case forecasts, should be treated with caution.

- [...] the cumulative uptake of the primary course of COVID-19 vaccination in the EU/EEA was 83.3% (country range: 35.2–94.7%) among adults aged 18 years and older and 72.5% (country range: 29.5–86.2%) in the total population. The cumulative uptake of a booster/additional dose was 63.7% (country range: 10.8–88.2%) among adults aged 18 years and older and 52.8% (country range: 8.8–70.6%) in the total population.
- The estimated distribution (median and range of values from 22 countries for weeks 11 – 12, 14 March to 27 March 2022) of variants of concern (VOCs) was 100.0% (63.9–100.0%) for B.1.1.529 (Omicron) and 0.0% (0.0–0.3%, 47 detections) for B.1.617.2 (Delta). The estimated distribution of Omicron sublineages in this period from 19 countries reporting data on sublineages at an adequate sequencing volume was 82.7% (55.8–98.9%) for BA.2, 17.1% (1.0–44.2%) for BA.1 and 0.2% (0.0–0.2%, 9 detections) for BA.3.”
- [ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines \[04-06-2022\]](#)
- [COVID-19: joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines \[04-06-2022\]](#)
- [Video: ECDC Director on fourth doses of mRNA COVID-19 vaccines \[04-06-2022\]](#)
- [COVID-19 situation update for the EU/EEA, as of 6 April 2022 \[04-06-2022\]](#)
- [Data on the daily number of new reported COVID-19 cases and deaths by EU/EEA country \[updated regularly\]](#)
- [Data on COVID-19 vaccination in the EU/EEA \[updated regularly\]](#)

FDA: U.S. Food & Drug Administration | [fda.gov](https://www.fda.gov)

- [Coronavirus \(COVID-19\) update: daily roundup \[updated regularly\]](#)
- [FDA updates Sotrovimab emergency use authorization \[04-05-2022\]](#)
 - “Sotrovimab is no longer authorized to treat COVID-19 in any U.S. region due to increases in the proportion of COVID-19 cases caused by the Omicron BA.2 sub-variant”

Public Health England | [gov.uk](https://www.gov.uk)

Note: Public Health England was replaced by [UK Health Security Agency](#) and [Office for Health Improvement and Disparities](#). These organizations are listed below under “Other relevant government organizations”

- [Location of Public Health England \(PHE\) functions from 1 October 2021](#)

World Health Organization | [who.int](https://www.who.int)

- [Clinical care of severe acute respiratory infections – tool kit \[04-06-2022\]](#)
- [Injection safety in the context of coronavirus disease \(COVID-19\) vaccination: addendum to policy brief, 5 April 2022 \[04-05-2022\]](#)
- [Coronavirus disease \(COVID-19\) weekly epidemiological update \[04-05-2022\]](#)
- [Coronavirus disease \(COVID-19\) weekly operational update \[03-30-2022\]](#)
- [Log of major changes and errata in WHO daily aggregate case and death count data \[updated regularly\]](#)
- [Draft landscape and tracker of COVID-19 candidate vaccines \[updated regularly\]](#)
- [Coronavirus disease \(COVID-2019\) press briefings \[audio posted first; transcripts posted later\]](#)
- [EPI-WIN: WHO information network for epidemics \[updated regularly\]](#)

Other relevant government bodies / health care organizations

- Government of Ontario
 - [Ontario expanding fourth-dose eligibility](#) [04-06-2022]
- Indigenous Services Canada
 - [Coronavirus \(COVID-19\) and Indigenous communities](#) [updated regularly]
- Prime Minister of Canada
 - [Prime Minister announces additional funding for COVID-19 vaccination in lower-income countries](#) [04-08-2022]
- Statistics Canada
 - [COVID-19: a data perspective](#) [updated regularly]
 - [Impacts of COVID-19 on Canadians – testing and vaccination, February 21 to March 13, 2022](#) [04-07-2022]
- National Institute on Ageing
 - [My COVID-19 visit risk](#) [no date]
- UK Health Security Agency
 - [COVID-19 variants: genomically confirmed case numbers](#) [updated 04-08-2022]
 - [Consensus statements on COVID-19](#) [updated 04-08-2022]
 - [SARS-CoV-2 variants of public health interest](#) [updated 04-08-2022]
 - [Investigation of SARS-CoV-2 variants: technical briefings](#) [updated 04-08-2022]
 - [The R value and growth rate](#) [updated 04-08-2022]
 - [National flu and COVID-19 surveillance reports published](#) [updated 04-07-2022]
 - [Weekly statistics for NHS Test and Trace \(England\): 24 to 30 March 2022](#) [04-07-2022]
 - [Prevalence of COVID-19 remains at high levels across the country](#) [04-06-2022]
 - [COVID-19 test validation approved products](#) [updated 04-06-2022]
 - [Consensus statements on COVID-19](#) [updated 04-06-2022]
 - [Antibody testing for SARS-CoV-2: extended information](#) [updated 04-05-2022]
 - [NHS COVID-19 app: privacy information](#) [updated 04-05-2022]
- UK Department of Health and Social Care
 - [Changes to Human Medicine Regulations to support the rollout of vaccines: one-year review - A report summarising the findings following a one-year review of the use of regulations 174A and 247A, implemented to support the rollout of COVID-19 and flu vaccines](#) [04-05-2022]
- UK Department for Education
 - [Laptops, tablets and connectivity progress data during the coronavirus \(COVID-19\) outbreak](#) [04-05-2022]
 - [Attendance in education and early years settings during the coronavirus \(COVID-19\) pandemic: 23 March 2020 to 31 March 2022](#) [04-05-2022]
- UK Department for Transport
 - [Transport use during the coronavirus \(COVID-19\) pandemic](#) [updated 04-06-2022]
- UK Medicines and Healthcare products Regulatory Agency
 - [Coronavirus \(COVID-19\) vaccines adverse reactions](#) [updated 04-07-2022]

- [Medical devices given exceptional use authorisations during the COVID-19 pandemic \[updated 04-04-2022\]](#)
- UK Office for National Statistics
 - [Coronavirus \(COVID-19\) infection survey, UK: 8 April 2022 \[04-08-2022\]](#)
 - [Updating ethnic contrasts in deaths involving the coronavirus \(COVID-19\), England: since 10 January 2022 \[04-07-2022\]](#)
 - [Prevalence of ongoing symptoms following coronavirus \(COVID-19\) infection in the UK: 7 April 2022 \[04-07-2022\]](#)
 - [Attitudes towards COVID-19 among passengers travelling into and out of the UK: September 2021 to February 2022 \[04-06-2022\]](#)
 - [Coronavirus \(COVID-19\) infection survey, UK: antibody and vaccination data, 6 April 2022 \[04-06-2022\]](#)
- UK Scientific Advisory Group for Emergencies
 - [CMMID: Network properties of the school system in England – implications for the effect of school reopening strategies on transmission of SARS-COV-2, 4 June 2020 \[04-08-2022\]](#)
 - [Imperial College London: Age dependence in COVID-19 infection and fatality risk, 11 February 2020 \[04-08-2022\]](#)
 - [Imperial College London: How do contact patterns affect variant of concern transmission advantage?, 14 January 2021 \[04-08-2022\]](#)
 - [Imperial College London: Intervention options and testing needs for long-term suppression of COVID-19 transmission, 28 April 2020 \[04-08-2022\]](#)
 - [Imperial College London: Modelling proposed UK exit strategies, 5 May 2020 \[04-08-2022\]](#)
 - [Imperial College London: Response to COVID-19 in South Korea and implications for UK exit strategies, 3 May 2020 \[04-08-2022\]](#)
 - [Isaac Newton Institute: Contact tracing, 9 June 2020 \[04-08-2022\]](#)
 - [Lancaster University: COVID-19 Bayesian Spatial Stochastic Model-based risk estimation, 3 August 2020 \[04-08-2022\]](#)
 - [Lancaster University: COVID-19 Bayesian Spatial Stochastic Model-based risk estimation, 8 September 2020 \[04-08-2022\]](#)
 - [Lancaster University: Spatial considerations for reliable national surveillance for COVID-19, 28 May 2020 \[04-08-2022\]](#)
 - [Lancaster University: UK COVID-19 LAD/Age model – situation report, 20 March 2020](#)
 - [LSHTM and University of Cambridge: SPI-Kids report – evaluating the increase in transmission for different back-to-back school scenarios, 30 April 2020 \[04-08-2022\]](#)
 - [LSHTM, University of Manchester and Alan Turing Institute: COVID-19 daily contact testing investigations, 2 March 2021 \[04-08-2022\]](#)
 - [LSHTM: Daily testing of contacts – adherence, number of tests, speed of tracing, and missed tests, 11 March 2021 \[04-08-2022\]](#)
 - [LSHTM: Estimating detection of infection among household gathering attendees based on one-off pre-gathering lateral flow tests, 2 December 2020 \[04-08-2022\]](#)

- [LSHTM: Modelling scenarios for relaxation of lockdown in England, 3 May 2020 \[04-08-2022\]](#)
- [LSHTM: Nowcasting the COVID-19 ICU demand in England, 19 March 2020 \[04-08-2022\]](#)
- [LSHTM: The possible impact of mask wearing outside the home on the transmission of COVID-19, 21 April 2020 \[04-08-2022\]](#)
- [PHE, LSHTM and University of Oxford: How many hospitalised cases are nosocomial or nosocomially linked?, 3 June 2020 \[04-08-2022\]](#)
- [PHE: Impact of gradual reopening strategies using POLYMOD contact data, 28 April 2020 \[04-08-2022\]](#)
- [PHE: Impact of gradual school reopening using POLYMOD contact data, 30 April 2020 \[04-08-2022\]](#)
- [PHE: Investigation of high risk exposure settings for COVID-19 in England, 2 December 2020 \[04-08-2022\]](#)
- [SPI-M-O: medium-term projections \(draft\), 1 September 2020 \[04-08-2022\]](#)
- [SPI-M-O: medium-term projections \(draft\), 15 September 2020 \[04-08-2022\]](#)
- [SPI-M-O: medium-term projections, 16 February 2022 \[04-08-2022\]](#)
- [SPI-M-O: medium-term projections, 16 March 2022 \[04-08-2022\]](#)
- [SPI-M-O: medium-term projections, 2 March 2022 \[04-08-2022\]](#)
- [SPI-M-O: medium-term projections, 23 February 2022 \[04-08-2022\]](#)
- [SPI-M-O: medium-term projections, 23 March 2022 \[04-08-2022\]](#)
- [SPI-M-O: medium-term projections, 9 March 2022 \[04-08-2022\]](#)
- [SPI-M-O: Sensitivity analysis of modelling – collaborative working document \(Draft\), 30 September 2020 \[04-08-2022\]](#)
- [SPI-M-O: Statement on population case detection – modelling assumptions \(Annex 1\), 9 September 2020 \[04-08-2022\]](#)
- [SPI-M-O: Update from regional variation group, 2 June 2021 \[04-08-2022\]](#)
- [University of Bristol and University of Exeter: Impact of opening schools on the effective reproduction number – analysis of the Social Contact Survey, 30 April 2020 \[04-08-2022\]](#)
- [University of Bristol: Strategies for reducing COVID-19 transmission with social distancing measures, 28 April 2020 \[04-08-2022\]](#)
- [University of Bristol: Strategies for reducing COVID-19 transmission with social distancing measures, 5 May 2020 \[04-08-2022\]](#)
- [University of Cambridge: Estimating R for intermittent interventions, 29 April 2020 \[04-08-2022\]](#)
- [University of Exeter and University of Bristol: Household networks and bubbling – insights from percolation theory, 14 May 2020 \[04-08-2022\]](#)
- [University of Exeter: Increased hazard of mortality in cases compatible with SARS-CoV-2 variant of concern 202012/1 - a retrospective case-control study, 19 January 2021 \[04-08-2022\]](#)
- [University of Manchester, University of Warwick and IBM Research: Bubbles during lockdown relaxation, 13 May 2020 \[04-08-2022\]](#)
- [University of Manchester: UK COVID-19 predictions, 23 March 2020 \[04-08-2022\]](#)

- [University of Oxford, LSHTM and University of Manchester, Alan Turing Institute: Effect of reducing isolation/quarantine period and potential trade-offs with the probability of case self-report and isolation/quarantine uptake, 10 November 2020 \[04-08-2022\]](#)
- [University of Warwick and LSHTM: The effectiveness of extended social bubbles as a soft exit strategy from the COVID-19 lockdown, 13 May 2020 \[04-08-2022\]](#)
- [University of Warwick: Assessment of changes to lockdown and other controls, 26 April 2020 \[04-08-2022\]](#)
- [University of Warwick: Circuit breakers - implementing \(partial\) lockdown for 2 weeks over half-term, 14 September 2020 \[04-08-2022\]](#)
- [University of Warwick: Impact of changes to school attendance, 28 April 2020 \[04-08-2022\]](#)
- [University of Warwick: Impact of uptake and adherence on transmission and absences resulting from secondary school reopening strategies involving rapid testing, 11 March 2021 \[04-08-2022\]](#)
- [University of Warwick: Simulations of potential exit strategies, 3 May 2020 \[04-08-2022\]](#)
- [Welsh Government TAC: Seasonal effects on COVID-19 in South America, 10 July 2020 \[04-08-2022\]](#)
- [Welsh Government TAG: Circuit breakers/ early warning indicator, 10 July 2020 \[04-08-2022\]](#)
- Centre for Global Infectious Disease Analysis
 - [Report 51 - Valuing lives, education and the economy in an epidemic: societal benefit of SARS-CoV-2 booster vaccinations in Indonesia \[02-14-2022\]](#)

CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu

- [Healthcare workers report high job turnover amid pandemic \[04-08-2022\]](#)
- [Study: About two thirds of Africans exposed to COVID-19 \[04-07-2022\]](#)
- [COVID patients may be at higher risk for blood clots for up to 6 months \[04-07-2022\]](#)
- [COVID-19 Scan for Apr 07, 2022: Fluvoxamine for COVID outpatients; COVID-19 and pulse oximetry \[04-06-2022\]](#)
- [COVID-19 health workers suffer combat-type moral trauma \[04-06-2022\]](#)
- [Biden moves on combating long COVID \[04-06-2022\]](#)
- [Global COVID cases fall for second week as BA.2 rises \[04-06-2022\]](#)
- [COVID-19 Scan for Apr 06, 2022: Efficacy of 4th COVID vaccine dose; C-sections, inductions during pandemic \[04-05-2022\]](#)
- [COVID vaccine in early pregnancy not tied to birth defects \[04-05-2022\]](#)
- [Global groups propose strategy to tackle ongoing COVID risks \[04-05-2022\]](#)
- [BA.2 now behind 72% of all US COVID-19 cases \[04-05-2022\]](#)

National Collaborating Centre for Environmental Health | ncceh.ca

- [April, 2022 environmental health research scan \(with COVID-19 section\) \[04-05-2022\]](#)
- [March, 2022 environmental health research scan \(with COVID-19 section\) \[03-16-2022\]](#)
- [The Omicron variant - updating our knowledge as the surge subsides \[02-15-2022\]](#)

ProMED | promedmail.org

- Latest on COVID-19 [individual posts]
- [COVID-19 update \(91\): birth data, BA.2 variant, WHO](#) [04-08-2022]
- [COVID-19 update \(90\): strategy, 2nd booster, WHO](#) [04-07-2022]
- [COVID-19 update \(89\): China, variants, WHO](#) [04-06-2022]
- [COVID-19 update \(88\): children, Sweden, diabetes risk, WHO, global](#) [04-03-2022]

Updated Daily

COVID-19 resources (case counts) | arcgis.com

- [Canada COVID-19](#)

COVID-19 Canada Open Data Working Group | [COVID-19 CODWG](#)

- [COVID-19 in Canada \(case count dashboard\)](#)

Johns Hopkins CCSE | systems.jhu.edu

- [2019-nCoV Global Cases \(by Johns Hopkins CSSE\)](#) [real-time tracking]
- [Resetting our response: changes needed in the US approach to COVID-19](#) [07-29-2020]

NextStrain | nextstrain.org

- [Phylogeny of SARS-like betacoronaviruses including novel coronavirus \(nCoV\)](#) [real-time tracking]
- [Genomic epidemiology of novel coronavirus \(nCoV\)](#) [real-time tracking]
- [Genomic analysis of nCoV spread. Situation report 2020-01-30](#) [real-time tracking]

Guidelines and Technical documents (updated weekly)

The guidelines listings are current to **04-06-2022**; posted **04-08-2022**

Section I: General Guidelines

Ontario / Canada Main Page

- [Ontario guidance](#)
- [Canadian guidance \(federal\)](#)

Reopening/Rebuilding Guidelines

Ontario

- ON [COVID-19 public health measures and advice](#) [no date]

Canada (federal) and provinces and territories (other than Ontario)

- CA [COVID-19: readiness criteria and indicators for easing restrictive public health measures](#) [05-14-2021]
- BC [B.C.'s response to COVID-19](#) [updated 03-23-2022]
- AB [COVID-19 public health actions](#) [no date]
- SK [Public health measures](#) [no date]
- MB [Manitoba Pandemic Response System](#) [no date]
- QC [About the measures in force](#) [no date]
- NB [Living with COVID-19](#) [no date]
- NL [Current Restrictions](#) [no date]
- PEI [COVID-19 \(coronavirus\) in Prince Edward Island](#) [no date]
- NS [Reopening plan](#) [updated regularly]
- NW [Restrictions and Moving Forward](#) [no date]
- YT [Forging ahead: the Yukon's continuing response to COVID-19](#) [no date]
- NT [Nunavut's Path: Living with COVID-19](#) [03/14/2022]
- [Guidance on re-opening northern, remote, isolated, and Indigenous communities](#) [no date]

WHO

- [Implementation guidance for assessments of frontline service readiness](#) [07-01-2021]
- [Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance](#) [06-14-2021]
- [Considerations for implementing and adjusting public health and social measures in the context of COVID-19](#) [11-04-2020]
- [WHO COVID-19 preparedness and response progress report - 1 February to 30 June 2020](#) [08-03-2020]

UK

- [Coronavirus \(COVID-19\): guidance on the phased return of elite sport](#) [updated 04-04-2022]
- [Our plan to rebuild: the UK government's COVID-19 recovery strategy](#) [07-24-2020]

ECDC

- [Data on country response measures to COVID-19](#) [updated 03-17-2022]
- [Introducing a coherent European framework for tuning COVID-19 response measures](#) [03-17-2021]

[Back to Top](#)

Vaccinations- General

Ontario Ministry of Health

- [COVID-19 vaccine-relevant information and planning resources](#) [updated 03-31-2022]
- [Ethical framework for COVID-19 vaccine distribution](#) [updated 03-31-2022]
- [Guidance for routine immunization services during COVID-19 version 2](#) [10-28-2021]

Canada (Federal)

- [An Advisory Committee Statement \(ACS\) National Advisory Committee on Immunization \(NACI\): Initial guidance on a second booster dose of COVID-19 vaccines in Canada](#) [04-05-2022]
- [Planning guidance for immunization clinics for COVID-19 vaccines](#) [03-30-2022]

- [COVID-19 vaccine guide for youth and adults \(12 years and over\): Overview](#) [02-02-2022]
- [Adjusting public health measures in the context of COVID-19 vaccination](#) [02-02-2022]
- [An Advisory Committee Statement \(ACS\) National Advisory Committee on Immunization \(NACI\) guidance on booster COVID-19 vaccine doses in Canada](#) [12-03-2021]
- [Summary of NACI rapid response of December 3, 2021: guidance on booster COVID-19 vaccine doses in Canada](#) [12-03-2021]
- [NACI interim guidance on booster COVID-19 vaccine doses in Canada](#) [10-29-2021]
- [For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines](#) [09-16-2021]
- [COVID-19 immunization: federal, provincial and territorial statement of common principles](#) [modified 08-11-2021]
- [Health care provider vaccine tool kit. version 2](#) [05-07-2021]
- [Planning guidance for administration of COVID-19 vaccine](#) [12-21-2020]
- [Canada's COVID-19 immunization plan: saving lives and livelihoods](#) [no date]
- [Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic](#) [10-14-2020]
- [Interim guidance on continuity of immunization programs during the COVID-19 pandemic](#) [05-13-2020]

Provinces and territories (other than Ontario)

- BC [Spikevax™ \(Moderna\)](#) [updated 04-04-2022]
- BC [COVID-19 vaccine Nuvaxovid™ \(Novavax\)](#) [updated 04-04-2022]
- BC [Vaxzevria™/COVISHIELD \(AstraZeneca/Verity Pharmaceuticals\)](#) [updated 04-04-2022]
- BC [COVID-19 vaccine Ad26.COV2.S \[recombinant\] \(Janssen\)](#) [updated 04-04-2022]
- BC [COVID-19 mRNA vaccine Comirnaty™ \(Pfizer-BioNTech\)](#) [updated 04-04-2022]
- BC [COVID-19 Vaccine ChAdOx1-S \[recombinant\]](#) [updated 04-04-2022]
- BC [COVID-19 vaccine eligibility](#) [updated 04-04-2022]
- BC [Novavax shipping, storage and use guidelines](#) [03-04-2022]
- BC [Novavax redistribution guidelines](#) [03-04-2022]
- BC [Immunization manual: summary of changes: admin circular](#) [03-04-2022]
- BC [COVID-19 vaccine screening checklist](#) [02-25-2022]
- BC [Pfizer redistribution guidelines](#) [02-08-2022]
- BC [World Health Organization \(WHO\) emergency use authorization \(EUA\) qualified COVID-19 vaccines](#) [01-31-2022]
- BC [Point of care risk assessment \(PCRA\)](#) [no date]
- BC [World Health Organization \(WHO\) emergency use authorization \(EUA\) qualified COVID-19 vaccines](#) [01-31-2022]
- BC [Janssen shipping, storage and use guideline](#) [01-17-2022]
- BC [Janssen redistribution guidelines](#) [01-17-2022]

- BC [Regulated and unregulated health professionals SARS-CoV-2 immunization order](#) [01-09-2022]
- BC [Emergency medical assistants SARS-CoV-2 immunization order](#) [updated 01-09-2022]
- BC [Moderna redistribution guidelines](#) [01-06-2022]
- BC [Administrative circular](#) [12-31-2021]
- BC [2021/22 seasonal influenza vaccine eligibility](#) [10-00-2021]
- BC [COVID-19 Pfizer vaccine shipping, storage, thawing and use guidelines](#) [10-15-2021]
- BC [Latex content in vaccines](#) [10-00-2021]
- BC [Immunization manual appendix A: informed consent \(page 4\)](#) [updated 09-00-2021]
- BC [Guidance for receiving and handling the Pfizer-BioNTech COVID-19 mRNA vaccine \(including dry ice procedures\)](#) [08-31-2021]
- BC [COVID-19 vaccination: why your 2nd dose is important](#) [08-27-2021]
- BC [Vaccine SOP: cold chain incident reporting process](#) [updated 07-21-2021]
- BC [Pfizer vaccine sub dose vial reporting](#) [07-13-2021]
- BC [COVID-19 Pfizer vaccine partial tray ULT distribution guidelines](#) [05-19-2021]
- BC [Cold chain assets warranty contact information](#) [05-05-2021]
- BC [Vaccine SOP: return of materials to manufacturers](#) [04-30-2021]

WHO

- [Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19v](#) [03-15-2022]
- [Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotech Group \(CNBG\), Sinopharm](#) [updated 03-15-2022]
- [Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac](#) [03-15-2022]
- [Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: Grading of evidence – Evidence to recommendations tables](#) [03-15-2022]
- [Annexes to the interim recommendations for use of the ChAdOx1-S \[recombinant\] vaccine against COVID-19 \(AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience\)](#) [03-15-2022]
- [Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: grading of evidence, evidence to recommendation tables](#) [03-15-2022]
- [Interim recommendations for use of the ChAdOx1-S \[recombinant\] vaccine against COVID-19 \(AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™\)](#) [03-15-2022]
- [Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19](#) [updated 02-23-2022]
- [NVX-CoV2373 recombinant, adjuvanted COVID-19 vaccine](#) [02-09-2022]
- [Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing](#) [01-21-2022]
- [COVAXIN® \(BBV152\) – Inactivated, COVID-19 vaccine](#) [01-10-2022]

- [Annexes to the interim recommendations for use of the Janssen Ad26.COVS.S vaccine](#) [12-09-2021]
- [Interim recommendations for the use of the Janssen Ad26.COVS.S \(COVID-19\) vaccine](#) [12-09-2021]
- [Guidance on operational microplanning for COVID-19 vaccination](#) [11-16-2021]
- [Injection safety in the context of coronavirus disease \(COVID-19\) vaccination](#) [11-05-2021]
- [Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP](#) [10-28-2021]
- [Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance](#) [10-21-2021]
- [How to manage COVID-19 vaccines without VVM at vaccination service points?](#) [08-31-2021]
- [Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® \(Tozinameran\)](#) [08-04-2021]
- [COVID-19 vaccine introduction and deployment costing tool \(CVIC tool\) version 2.2](#) [06-10-2021]
- [Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines](#) [06-01-2021]
- [Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19:](#) [06-01-2021]
- [Technical note on delayed shipments for the ChAdOx1-S \[recombinant\] vaccines: what are the implications for the administration of second doses?: Scientific brief](#) [05-26-2021]
- [Health worker communication for COVID-19 vaccination flow diagram](#) [05-13-2021]
- [AstraZeneca ChAdOx1-S/nCoV-19 \[recombinant\], COVID-19 vaccine: COVID-19 vaccine explainer](#) [05-10-2021]
- [AstraZeneca ChAdOx1-S \[recombinant\], COVID-19 vaccine](#) [05-10-2021]
- [Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections \(SARI\) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design](#) [05-07-2021]
- [COVID-19 exercise programme - drills for vaccine deployment](#) [05-03-2021]
- [Why are there extra doses of vaccine in the vaccine vial?](#) [04-16-2021]
- [COVID-19 and mandatory vaccination: ethical considerations and caveats](#) [04-13-2021]
- [Data for action: achieving high uptake of COVID-19 vaccines: interim guidance](#) [04-01-2021]
- [Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption](#) [11-01-2020]

CDC

- [Stay up to date with your COVID-19 vaccines](#) [updated 04-02-2022]
- [COVID-19 vaccine booster shots](#) [updated 04-01-2022]
- [Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 \(COVID-19\) pandemic](#) [updated 03-22-2022]
- [Understanding Viral Vector COVID-19 Vaccines](#) [updated 03-14-2022]
- [COVID-19 vaccine reporting systems](#) [updated 01-04-2022]
- [Communication resources for COVID-19 vaccines](#) [12-11-2021]

- [COVID-19 vaccination clinical & professional resources](#) [12-01-2021]
- [COVID-19 vaccination program operational guidance](#) [10-14-2021]
- [Public health investigations of COVID-19 vaccine breakthrough cases: Case investigations protocol](#) [no date]
- [Interim guidance for routine and influenza immunization services during the COVID-19 Pandemic](#) [04-15-2021]
- [Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization](#) [04-14-2021]

UK

- [National protocol for COVID-19 Vaccine AstraZeneca \(ChAdOx1-S \[recombinant\]\)](#) [updated 04-01-2022]
- [National protocol for Comirnaty® 30microgram/dose COVID-19 mRNA vaccine](#) [updated 04-01-2022]
- [National protocol for Spikevax \(formerly COVID-19 vaccine Moderna\)](#) [updated 04-01-2022]
- [Monitoring reports of the effectiveness of COVID-19 vaccination](#) [updated 03-25-2022]
- [COVID-19 vaccination programme](#) [updated 03-17-2022]
- [COVID-19 vaccination: information for healthcare practitioners](#) [updated 03-10-2022]
- [COVID-19: the green book, chapter 14a](#) [updated 02-28-2022]
- [COVID-19 vaccination: vaccine product information](#) [02-23-2022]
- [COVID-19 vaccination: blood clotting information for healthcare professionals](#) [updated 02-14-2022]
- [COVID-19 vaccination: booster dose resources](#) [updated 02-02-2022]
- [National protocol for COVID-19 mRNA vaccine BNT162b2 \(Pfizer/BioNTech\)](#) [11-20-2021]
- [COVID-19 vaccination: what to expect after vaccination](#) [updated 11-09-2021]
- [Monitoring of the effectiveness of COVID-19 vaccination](#) [09-14-2021]
- [COVID-19: vaccine surveillance strategy](#) [03-29-2021]

ECDC

- [Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update](#) [03-14-2022]
- [Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA](#) [01-31-2022]
- [Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA](#) [12-14-2021]
- [Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA](#) [10-15-2021]
- [Infographic: facilitating COVID-19 vaccination acceptance and uptake](#) [10-15-2021]
- [Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0](#) [10-08-2021]
- [Interim public health considerations for the provision of additional COVID-19 vaccine doses](#) [09-01-2021]

- [Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence](#) [07-22-2021]
- [Countering online vaccine misinformation in the EU/EEA](#) [06-29-2021]
- [Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making](#) [05-18-2021]
- [Objectives of vaccination strategies against COVID-19](#) [04-23-2021]
- [Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions](#) [04-21-2021]
- [Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice](#) [03-29-2021]
- [Stress test on logistical aspects of COVID-19 vaccination deployment plans: final report](#) [02-03-2021]
- [Integrated COVID-19 response in the vaccination era](#) [02-01-2021]
- [COVID-19 vaccination and prioritisation strategies in the EU/EEA](#) [12-22-2020]

Australia

- [ATAGI recommendations on the use of a booster dose of COVID-19 vaccine](#) [updated 03/28/2022]
- [Clinical recommendations for COVID-19 vaccines](#) [updated 03/25/2022]
- [COVID-19 vaccination – information on COVID-19 Pfizer \(COMIRNATY\) vaccine](#) [updated 03-28-2022]
- [ATAGI clinical guidance for COVID-19 vaccine providers](#) [02/23/2022]
- [COVID-19 vaccination – ATAGI guidance on the use of multi-dose vials for COVID-19 vaccination](#) [02-20-2022]
- [COVID-19 vaccination – vaccine dose policy](#) [updated 02-07-2022]
- [COVID-19 vaccination – updated provider kit for general practices](#) [12-14-2021]
- [COVID-19 vaccination – consent – information for providers: COVID-19 vaccination consent and FAQs](#) [11-04-2021]
- [Op COVID SHIELD national COVID vaccine campaign plan](#) [08-03-2021]

[Back to Top](#)

Vaccinations- Specific populations

Canada (Federal)

- [NACI rapid response: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age](#) [modified 03-24-2022]
- [NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age](#) [modified 03-17-2022]
- [COVID-19: recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study](#) [modified 03-11-2022]
- [NACI rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2](#) [modified 02-09-2022]
- [Quick reference guide on use of COVID-19 vaccines for children 5 to 11 years of age: overview](#) [modified 02-03-2022]

- [Planning for the 2021-2022 school year in the context of COVID-19 vaccination](#) [modified 02-02-2022]
- [Archived: National Advisory Committee on Immunization \(NACI\) statement: recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine \(10 mcg\) in children 5 to 11 years of age](#) [updated 01-25-2022]
- [NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines](#) [12-03-2021]
- [Summary of NACI rapid response of December 3, 2021: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines](#) [12-03-2021]

Provinces and territories (other than Ontario)

- BC [COVID-19 mRNA vaccine Comirnaty™ \(Pfizer-BioNTech\) adult/adolescent](#) [updated 04-04-2022]
- BC [Health professionals COVID-19 vaccination status information and preventive measures – March 7, 2022](#) [03-08-2022]
- BC [COVID-19 vaccination for children age 5-11 frequently asked questions for community practitioners](#) [03-07-2022]
- BC [RESIDENTIAL CARE COVID-19 VACCINATION STATUS](#) [02-28-2022]

WHO

- [Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons](#) [10-25-2021]
- [Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women](#) [06-10-2021]
- [Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021](#) [04-26-2021]

CDC

- [Resources to Promote the COVID-19 Vaccine for Children & Teens](#) [updated 03-31-2022]
- [COVID-19 vaccines for children and teens](#) [updated 03-30-2022]
- [COVID-19 vaccine equity for racial and ethnic minority groups](#) [updated 03-29-2022]
- [COVID-19 vaccines while pregnant or breastfeeding](#) [updated 03-03-2022]
- [COVID-19 vaccines for people who would like to have a baby](#) [updated 03-03-2022]
- [COVID-19 vaccination considerations for persons with underlying medical conditions](#) [updated 02-25-2022]
- [COVID-19 vaccine information for specific groups](#) [updated 02-18-2022]
- [Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access](#) [updated 01-20-2022]
- [Guidance for vaccinating older adults and people with disabilities at vaccination sites](#) [08-10-2021]
- [Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness](#) [4-30-2021]

UK

- [COVID-19 vaccination: resources for children aged 5 to 11 years](#) [updated 03-28-2022]

- [COVID-19 vaccination: resources for children and young people aged 12 to 17 years](#) [updated 02-01-2022]
- [COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding](#) [updated 02-02-2022]
- [COVID-19 vaccination: guide for adults](#) [updated 01-19-2022]
- [Interim public health considerations for COVID-19 vaccination of children aged 5-11 years](#) [12-01-2021]
- [Safety of COVID-19 vaccines when given in pregnancy](#) [04-30-2021]

ECDC

- [Data collection on COVID-19 outbreaks in closed settings: long-term care facilities, version 2.1](#) [02-18-2022]
- [COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose](#) [02-08-2022]
- [Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA](#) [06-01-2021]

Australia

- [COVID-19 vaccination – COVID-19 vaccine information for the residential aged care workforce](#) [03-29-2022]
- [COVID-19 vaccination – COVID-19 vaccination decision guide for frail older people, including those in residential aged care facilities](#) [updated 03-28-2022]
- [ATAGI – COVID-19 vaccination – shared decision making guide for people with immunocompromise](#) [updated 03-28-2022]
- [COVID-19 vaccination – shared decision making guide for people receiving palliative care or end-of-life care](#) [updated 03-28-2022]
- [ATAGI – provider guide to COVID-19 vaccination of people with immunocompromise](#) [updated 03-28-2022]
- [ATAGI expanded guidance on temporary medical exemptions for COVID-19 vaccines](#) [updated 02-25-2022]
- [COVID-19 vaccination – vaccine dose policy- aged cared facilities](#) [updated 02-07-2022]
- [COVID-19 vaccination – COVID-19 vaccination decision guide for women who are pregnant, breastfeeding or planning pregnancy](#) [updated 12-24-2021]

[Back to Top](#)

Vaccinations- Adverse Effects

Canada (Federal)

- [National Advisory Committee on Immunization \(NACI\): rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines](#) [12-03-2021]
- [Reports of myocarditis and pericarditis after COVID-19 vaccination: communiqué to health practitioners \(June 3, 2021\)](#) [06-14-2021]

Provinces and territories (other than Ontario)

- BC [Guidance document on the management of inadvertent vaccine errors](#) [02-04-2022]
- BC [Guidance on the Management of Inadvertent COVID-19 Vaccine Errors](#) [02-04-2022]

- BC [COVID-19 vaccine planning guide for people who are pregnant or breastfeeding](#) [10-12-2021]
- BC [Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine](#) [06-11-2021]
- BC [Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults](#) [no date]
- BC [Clinical care guidance on vaccine-induced immune thrombotic thrombocytopenia \(VITT\), also known as thrombosis with thrombocytopenia syndrome \(TTS\)](#) [04-30-2021]

CDC

- [Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination](#) [02-11-2022]
- [Possible side effects after getting a COVID-19 vaccine](#) [01-12-2022]
- [Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination](#) [reviewed 08-09-2021]

WHO

- [How to manage COVID-19 vaccines without VVM at vaccination service points?](#) [08-31-2021]
- [COVID-19 vaccines: safety surveillance manual. Module on safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women](#) [07-12-2021]
- [How to monitor and report COVID-19 vaccine side effects](#) [03-15-2021]

UK

- [Coronavirus \(COVID-19\) vaccine adverse reactions](#) [updated 03-31-2022]
- [COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals](#) [updated 03-21-2022]
- [Myocarditis and pericarditis after COVID-19 vaccination](#) [updated 03-21-2022]
- [COVID-19 vaccination: Guillain-Barré Syndrome information for healthcare professionals](#) [updated 12-17-2021]
- [Safety of COVID-19 vaccines when given in pregnancy](#) [04-30-2021]

Australia

- [ATAGI clinical guidance on COVID-19 vaccine administration errors](#) [03-04-2022]
- [COVID-19 vaccination – primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine](#) [updated 03-01-2022]
- [COVID-19 vaccination – guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines](#) [12-02-2021]

[Back to Top](#)

Background Information/Case Definitions

Ontario Ministry of Health

- [Ontario case definition - coronavirus disease \(COVID-19\)](#) [01-17-2022]

PHAC

- [National case definition: coronavirus disease \(COVID-19\)](#) [updated 04-01-2022]
- [COVID-19 case report form](#) [01-11-2021]

CDC

- [Coronavirus disease 2019 \(COVID-19\) 2020 interim case definition, approved August 5, 2020](#) [04-16-2021]

WHO

- [A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021](#) [10-06-2021]

ECDC

- [Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA](#) [04-08-2021]
- [Rapid risk assessment: increased transmission of COVID-19 in the EU/EEA and the UK – thirteenth update](#) [10-23-2020]

UK

- [COVID-19: background information](#) [10-06-2021]
- [COVID-19: epidemiology, virology and clinical features](#) [10-06-2021]

Australia

- [COVID-19 disease, symptoms and variants](#) [updated 12-23-2021]

Other

- [BMJ best practice COVID-19](#) [updated regularly]

[Back to Top](#)

Laboratories

Ontario Ministry of Health

- [COVID-19 integrated testing & case, contact and outbreak management: interim guidance: Omicron surge version 3.0 amended](#) [03-28-2022]
- [Community labs and specimen collection centres: version 3](#) [03-29-2020]

PHAC

- [Biosafety advisory: SARS-CoV-2 \(severe acute respiratory syndrome-related coronavirus 2\)](#) [11-23-2021]
- [Polymerase chain reaction \(PCR\) and cycle threshold \(Ct\) values in COVID-19 testing](#) [06-10-2021]
- [National polymerase chain reaction \(PCR\) testing indication guidance for COVID-19](#) [10-07-2020]
- [Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance](#) [04-28-2020]

WHO

- [Acknowledgements: the Unity Studies for sero-epidemiological investigation of COVID-19](#) [updated 03-24-2022]
- [Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2](#) [03-30-2021]
- [Laboratory biosafety guidance related to coronavirus disease \(COVID-19\)](#) [01-28-2021]
- [COVID-19 new variants: knowledge gaps and research](#) [01-12-2021]

- [Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health](#) [01-08-2021]
- [SARS-CoV-2 genomic sequencing for public health goals](#) [01-08-2021]
- [SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide](#) [12-21-2020]
- [Assessment tool for laboratories implementing SARS-CoV-2 testing](#) [10-23-2020]
- [Diagnostic testing for SARS-CoV-2: interim guidance](#) [09-11-2020]
- [Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays](#) [09-11-2020]

CDC

- [How to report COVID-19 laboratory data](#) [updated 04-04-2022]
- [Guidance for SARS-CoV-2 point-of-care and rapid testing](#) [updated 04-04-2022]
- [Testing strategies for SARS-CoV-2](#) [updated 04-04-2022]
- [Guidance for reporting SARS-CoV-2 sequencing results](#) [03-21-2022]
- [Evaluation for SARS-CoV-2 testing in animals](#) [updated 03-30-2022]
- [Guidance for general laboratory safety practices during the COVID-19 pandemic](#) [updated 03-02-2022]
- [Using antibody tests for COVID-19](#) [updated 02-24-2022]
- [Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings](#) [updated 01-24-2022]
- [Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 \(COVID-19\)](#) [12-13-2021]
- [Frequently asked questions on COVID-19 testing for laboratories](#) [11-12-2021]
- [Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity](#) [10-29-2021]
- [Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19](#) [10-25-2021]
- [Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination](#) [08-09-2021]
- [Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing](#) [06-30-2021]
- [Variants and genomic surveillance for SARS-CoV-2](#) [04-02-2021]
- [Resources for laboratories working on coronavirus \(COVID-19\)](#) [03-28-2021]
- [Information for laboratories about coronavirus \(COVID-19\)](#) [03-28-2021]
- [SARS-CoV-2 viral culturing at CDC](#) [12-29-2020]
- [Serology testing for COVID-19 at CDC](#) [11-03-2020]

UK

- [Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens \(lateral flow devices\)](#) [updated 04-04-2022]
- [National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests](#) [updated 04-04-2022]
- [Technical validation protocol for SARS-CoV-2 nucleic acid detection](#) [updated 04-04-2022]

- [Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens \(lateral flow devices\)](#) [updated 04-04-2022]
- [Coronavirus \(COVID-19\) testing in adult care homes](#) [updated 04-01-2022]
- [NHS test and trace statistics \(England\): methodology](#) [updated 03-18-2022]
- [How tests and testing kits for coronavirus \(COVID-19\) work](#) [updated 02-14-2022]
- [Surge testing for new coronavirus \(COVID-19\) variants](#) [updated 08-16-2021]
- [Maintaining records of staff, customers and visitors to support NHS Test and Trace](#) [07-20-2021]
- [COVID-19: guidance for sampling and for diagnostic laboratories](#) [03-29-2021]

ECDC

- [The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates](#) [05-10-2021]

Australia

- [PHLN guidance on laboratory testing for SARS-CoV-2 \(the virus that causes COVID-19\)](#) [01-28-2022]

Other

- BC [PHO order on health authority regulated health professionals SARS-CoV-2 swabbing](#) [11-16-2020]
- BC [PHO order on midwives and certified practice speech language pathologists SARS-CoV-2 swabbing](#) [11-16-2020]
- BC [PHO order on British Columbia emergency health services SARS-CoV-2 swabbing](#) [11-16-2020]

[Back to Top](#)

Miscellaneous Guidelines

PHAC

- [COVID-19 and people with disabilities in Canada](#) [updated 04-04-2022]
- [Federal/provincial/territorial public health response plan for ongoing management of COVID-19](#) [updated 03-31-2022]
- [Individual and community-based measures to mitigate the spread of COVID-19 in Canada](#) [02-02-2022]
- [COVID-19: safety advice for private indoor gatherings](#) [12-23-2021]

Canadian provinces and territories (other than Ontario)

- BC [COVID-19 ethical decision-making framework](#) [12-24-2020]

WHO

- [Summary: Consolidated financing framework for ACT-accelerator agency and in-country needs](#) [02-16-2022]
- [Consolidated financing framework for ACT-A agency & in-country needs](#) [02-09-2022]
- [ACT-Accelerator 'fair share asks' - by country](#) [02-09-2022]
- [WHO technical consultation on oxygen access scale-up for COVID-19](#) [07-14-2021]
- [Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition](#) [07-09-2021]

- [Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance](#) [06-14-2021]
- [Critical preparedness, readiness and response actions for COVID-19: interim guidance](#) [05-27-2021]

CDC

- [Wildfire smoke and COVID-19: frequently asked questions and resources for air resource advisors and other environmental health professionals](#) [reviewed 01-31-2022]
- [Public health guidance for potential COVID-19 exposure associated with travel](#) [updated 01-27-2022]
- [Return to work criteria for healthcare personnel with SARS-CoV-2 infection \(interim guidance\)](#) [updated 01-21-2022]
- [Operational considerations for personal protective equipment in the context of global supply shortages for coronavirus disease 2019 \(COVID-19\) pandemic: non-US healthcare settings: Archived](#) [11-04-2021]
- [RRT composition: COVID-19 considerations](#) [03-01-2021]
- [Managing investigations during an outbreak](#) [07-31-2020]
- [Optimizing supply of PPE and other equipment during shortages](#) [07-16-2020]

ECDC

- [COVID-19 – high risk shielded patient list identification methodology. Version 12](#) [11-29-2021]
- [One-day in-action review \(IAR\) protocol in the context of COVID-19](#) [03-00-2021]
- [Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA](#) [02-17-2021]
- [Conducting in-action and after-action reviews of the public health response to COVID-19](#) [06-04-2020]

Australia

- [CDNA National guidelines for public health units](#) [updated 03-22-2022]

Other

- [Public health ethics and COVID-19: selected resources](#) – National Collaborating Centre for Healthy Public Policy [11-30-2021]

[Back to Top](#)

Data & Surveillance

Canada

- [COVID-19 data trends](#) [modified 04-01-2022]
- [Mathematical modelling and COVID-19](#) [modified 04-01-2022]
- [National surveillance guidelines for coronavirus disease \(COVID-19\)](#) [03-19-2021]

WHO

- [WHO COVID-19 essential supplies forecasting tool \(COVID-ESFT\)](#) [updated 02-15-2022]
- [Public health surveillance for COVID-19: interim guidance](#) [updated 02-14-2022]
- [End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance](#) [01-31-2022]

- [Enhancing readiness for Omicron \(B.1.1.529\): technical brief and priority actions for Member States](#) [01-21-2022]

CDC

- [National wastewater surveillance system \(NWSS\)](#) [updated 03-21-2022]
- [Wastewater surveillance data reporting & analytics](#) [updated 03-08-2022]
- [Wastewater surveillance testing methods](#) [01-26-2022]
- [Public health interpretation and use of wastewater surveillance data](#) [01-26-2022]
- [Developing a wastewater surveillance sampling strategy](#) [01-26-2022]
- [Targeted wastewater surveillance at facilities, institutions, and workplaces](#) [01-26-2022]
- [COVID-19 serology surveillance](#) [03-11-2021]
- [Data visualization](#) [02-16-2021]
- [Guide to global digital tools for COVID-19 response](#) [10-23-2020]
- [Large-scale geographic seroprevalence surveys](#) [10-02-2020]

ECDC

- [Organisation of vector surveillance and control in Europe](#) [12-13-2021]
- [Surveillance of COVID-19 in long-term care facilities in the EU/EEA](#) [11-29-2021]
- [Epidemiological update: Omicron variant of concern \(VOC\) – data as of 29 November 2021 \(12:30\)](#) [11-29-2021]
- [COVID-19 variants: genomically confirmed case numbers](#) [updated 11-29-2021]
- [Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1. 529 variant of concern \(Omicron\) for the EU/EEA](#) [11-26-2021]
- [COVID-19 surveillance guidance - transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens](#) [10-18-2021]
- [Guidance for representative and targeted genomic SARS-CoV-2 monitoring](#) [05-03-2021]

UK

- [COVID-19 surveillance in school KIDs \(sKIDs\): pre and primary schools](#) [09-04-2020]

[Back to Top](#)

Variants – Omicron

Canada

- [SARS-CoV-2 variants: national definitions, classifications and public health actions](#) [03-09-2022]

Ontario Ministry of Health

- [COVID-19 interim guidance: Omicron surge management of critical staffing shortages in highest risk settings. Version 4.0](#) [updated 03-31-2022]

CDC

- [Omicron variant: what you need to know](#) [updated 03-29-2022]

UK

- [Investigation of SARS-CoV-2 variants: technical briefings](#) [updated 03-25-2022]
- [SARS-CoV-2 variants of public health interest](#) [updated 03-25-2022]
- [COVID-19: investigation and initial clinical management of possible cases](#) [updated 03-25-2022]
- [SARS-CoV-2 Omicron VOC: investigating and managing suspected or confirmed cases](#) [updated 12-23-2021]

- [Methods for the detection and characterisation of SARS-CoV-2 variants – first update](#) [12-20-2021]

ECDC

- [Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the EU/EEA, 19th update](#) [updated 01-27-2022]
- [Threat assessment brief: implications of the further emergence and spread of the SARS CoV 2 B.1.1.529 variant of concern \(Omicron\) fo the EU/EEA first update](#) [12-02-2021]
- [Epidemiological update: Omicron variant of concern \(VOC\) – data as of 30 November 2021 \(12.00\)](#) [11-30-2021]
- [Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1. 529 variant of concern \(Omicron\) for the EU/EEA](#) [11-26-2021]

WHO

- [Enhancing readiness for Omicron \(B.1.1.529\): technical brief and priority actions for member states](#) [updated 01-21-2022]

Testing

Canada

- [Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan](#) [updated 09-08-2021]
- [Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection](#) [02-23-2021]
- [Guidance for repeated PCR testing in individuals previously positive for COVID-19](#) [12-08-2020]
- [National polymerase chain reaction \(PCR\) testing indication guidance for COVID-19](#) [10-07-2020]

Ontario Ministry of Health

- [COVID-19 Integrated Testing & Case, Contact and Outbreak Management nterim Guidance: Omicron Surge](#) [amended 03-28-2022]
- [COVID-19 guidance: testing of asymptomatic persons in pharmacies. Version 2](#) [11-18-2021]
- [COVID-19 test requisition](#) [06-12-2021]
- [Considerations for privately-initiated testing. version 3.0](#) [05-21-2021]
- [COVID-19 guidance: considerations for rapid antigen screening. Version 2.0](#) [02-17-2021]
- [Considerations for employer rapid antigen screening pilot](#) [11-20-2020]
- [COVID-19 surveillance testing – guidance regarding retirement homes staff and resident testing](#) [06-09-2020]

Canadian provinces and territories (other than Ontario)

- BC [COVID-19: viral testing guidelines for British Columbia](#) [updated 03-23-2022]
- BC [COVID-19 infection prevention and control: guidance for test collection & assessment centres](#) [09-09-2021]
- BC [Infection prevention and control guidance for test collection and assessment centres](#) [09-09-2021]
- BC [Antibody testing \(serology\) page](#) [no date]
- BC [Guideline for the appropriate use of SARS-CoV-2 \(COVID-19\) antibody \(serology\) testing](#) [08-14-2020]

WHO

- [Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing](#) [03-09-2022]

CDC

- [Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community](#) [updated 04-04-2022]
- [Guidance for SARS-CoV-2 point-of-care and rapid testing](#) [updated 04-04-2022]
- [Using antibody tests for COVID-19](#) [updated 02-24-2022]
- [SARS-CoV-2 antigen testing in long term care facilities](#) [updated 02-17-2022]
- [Interim guidance for SARS-CoV-2 testing in correctional and detention facilities](#) [updated 02-15-2022]
- [Overview of testing for SARS-CoV-2 \(COVID-19\)](#) [updated 02-11-2022]
- [Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 \(COVID-19\) pandemic](#) [updated 02-02-2022]
- [Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes: nursing homes & long-term care facilities](#) [updated 02-02-2022]
- [Testing strategies for SARS-CoV-2](#) [updated 12-28-2021]
- [CDC's diagnostic test for COVID-19 only and supplies](#) [10-05-2021]
- [Guidance for health departments about COVID-19 testing in the community](#) [08-30-2021]
- [CDC diagnostic tests for covid-19](#) [08-07-2021]
- [Nucleic acid amplification tests \(NAATs\)](#) [06-14-2021]
- [Guidance for healthcare workers about COVID-19 \(SARS-CoV-2\) testing](#) [06-14-2021]
- [Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings](#) [03-29-2021]
- [Serology testing for COVID-19 at CDC](#) [11-03-2020]

UK

- [Investigation of SARS-CoV-2 variants: technical briefings](#) [updated 03-25-2022]
- [Investigation of SARS-CoV-2 variants of concern: variant risk assessments](#) [updated 03-25-2022]
- [SARS-CoV-2 variants of public health interest](#) [updated 03-25-2022]
- [Testing for coronavirus \(COVID-19\) before hospital](#) [updated 03-08-2022]
- [Coronavirus COVID-19 serology and viral detection tests: technical validation reports](#) [updated 02-18-2022]
- [How tests and testing kits for coronavirus \(COVID-19\) work](#) [updated 02-14-2022]
- [Investigation of SARS-CoV-2 variants of concern: technical briefings](#) [09-17-2021]
- [Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021](#) [07-16-2021]
- [Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021](#) [07-16-2021]
- [SARS-CoV-2 variant of concern diagnostic assurance](#) [07-15-2021]
- [SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence](#) [10-16-2020]

ECDC

- [Considerations for the use of antibody tests for SARS-CoV-2 – first update](#) [02-10-2022]
- [Methods for the detection and identification of SARS-CoV-2 variants- first update](#) [12-20-2021]
- [Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories](#) [12-20-2021]
- [Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK](#) [10-26-2021]
- [Considerations on the use of rapid antigen detection \(including self-\) tests for SARS-CoV-2 in occupational settings](#) [05-06-2021]

- [Considerations for the use of saliva as sample material for COVID-19 testing](#) [05-03-2021]
- [Considerations on the use of self-tests for COVID-19 in the EU/EEA](#) [03-17-2021]
- [Guidance for COVID-19 quarantine and testing of travellers](#) [03-12-2021]
- [Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA](#) [02-16-2021]
- [Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update](#) [02-15-2021]
- [COVID-19 testing strategies and objectives](#) [09-18-2020]
- [Objectives for COVID-19 testing in school settings](#) [08-10-2020]

Australia

- [PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests](#) [updated 02-02-2022]
- [PHLN guidance on laboratory testing for SARS-CoV-2 \(the virus that causes COVID-19\)](#) [01-28-2022]

[Back to Top](#)

Symptoms/Treatment

Canada

- [Considerations for the use of nirmatrelvir/ritonavir to treat COVID-19 in the context of limited supply](#) [modified 02-24-2022]
- [COVID-19 for health professionals: treatments](#) [modified 02-01-2022]
- [COVID-19 signs, symptoms and severity of disease: a clinician guide](#) [modified 12-09-2021]
- [Non-contact infrared thermometers \(NCIT\)](#) [01-28-2021]

Ontario Ministry of Health

- [COVID-19 reference document for symptoms v. 9.0](#) [updated 01-04-2022]
- [Guidance for employers managing workers with symptoms within 48 hours of COVID-19 immunization. Version 3](#) [11-30-2021]
- [COVID-19 patient screening guidance document version 5.0](#) [08-26-2021]

WHO

- [Living guidance for clinical management of COVID-19](#) [11-23-2021]
- [COVID-19 disease in children and adolescents: scientific brief, 29 September 2021](#) [09-29-2021]
- [Neurology and COVID-19: scientific brief, 29 September 2021](#) [09-29-2021]
- [WHO living guideline: drugs to prevent COVID-19](#) [03-02-2021]
- [Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance](#) [08-12-2020]

CDC

- [Caring for post-COVID conditions](#) [updated 03-21-2022]
- [Clinical care quick reference for COVID-19](#) [updated 03-16-2022]
- [Care for breastfeeding people: Interim Guidance on Breastfeeding and Breast Milk Feeds in the Context of COVID-19](#) [updated 02-25-2022]
- [Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers](#) [updated 02-15-2022]
- [Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19](#) [updated 02-15-2022]

- [If You Are Sick or Caring for Someone](#) [02-09-2022]
- [Ending home isolation for persons with COVID-19 not in healthcare settings](#) [updated 01-14-2022]
- [Ending isolation and precautions for people with COVID-19: interim guidance](#) [updated 01-14-2022]
- [Standard operating procedure \(SOP\) for triage of suspected COVID-19 patients in non-US healthcare settings: early identification and prevention of transmission during triage](#) [10-18-2021]
- [Evaluating and caring for patients with post-COVID conditions: interim guidance](#) [06-14-2021]
- [Interim clinical guidance for management of patients with confirmed coronavirus disease \(COVID-19\)](#) [02-16-2021]
- [Assessing risk factors for severe COVID-19 illness](#) [11-30-2020]

WHO

- [Therapeutics and COVID-19](#) [updated 03-03-2022]
- [COVID-19 clinical care pathway \(CARE\): confirm, assess, respond, evaluate](#) [02-04-2022]
- [COVID-19 clinical care pathway \(CARE\): confirm SARS-CoV-2 infection, assess symptoms, risk factors and severity, respond with appropriate care and treatment, evaluate clinical response and recovery](#) [02-04-2022]
- [COVID-19 clinical management: living guidance](#) [11-23-2021]
- [Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection](#) [07-15-2021]
- [Hypertension and COVID-19](#) [06-17-2021]
- [WHO Information note: COVID-19 considerations for tuberculosis \(TB\) care](#) [05-05-2021]
- [Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021](#) [04-24-2021]
- [WHO COVID-19 clinical care bundle](#) [04-23-2021]
- [Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance](#) [08-13-2020]

US NIH

- [COVID-19 treatment guidelines](#) [updated 04-01-2022]

UK

- [COVID-19: migrant health guide](#) [updated 03-08-2022]
- [COVID-19: long-term health effects](#) [04-30-2021]

Australia

- [Coronavirus \(COVID-19\) – identifying the symptoms](#) [last updated 11-11-2020]

[Back to Top](#)

COVID-19 Diagnosis in Children

Canada

- [COVID-19 signs, symptoms and severity of disease: multisystem inflammatory syndrome - children \(MIS-C\)](#) [12-09-2021]

Ontario

- [Appendix 8: cases with positive COVID-19 serology results and management of cases with multisystem inflammatory syndrome in children \(MIS-C\) temporally associated with COVID-19. Version 2.0](#) [02-18-2021]

WHO

- [COVID-19 disease in children and adolescents: Scientific brief, 29 September 2021](#) [09-29-2021]

CDC

- [Information for healthcare providers about multisystem inflammatory syndrome in children \(MIS-C\)](#) [05-20-2021]

Other

- BC [Children with immune compromise](#) [11-30-2021]
- American Academy of Pediatrics [What is the case definition of multisystem inflammatory syndrome in children \(MIS-C\) interim guidance](#) [11-15-2021]
- BC [Pediatric clinical guidance for COVID-19](#) [09-27-2021]
- BC [Multisystem inflammatory syndrome in children \(MIS-C\) temporally associated with COVID-19: guidance for clinicians in B.C.](#) [07-05-2021]
- BC [Guidance for newborn care, resuscitation procedures and lactation](#) [06-11-2021]
- BC [Management of severe respiratory illness in pediatric patients during the COVID-19 pandemic](#) [05-12-2021]

Post-COVID-19 Condition

Canada

- [Post COVID-19 condition](#) [09-24-2021]

Ontario

- Science Table [Understanding the post COVID-19 condition \(long COVID\) and the expected burden for Ontario](#) [09-14-2021]

WHO

- [Evaluating and caring for patients with post-COVID conditions: interim guidance](#) [06-14-2021]
- [Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021](#) [04-24-2021]

CDC

- [Caring for post-COVID conditions](#) [03-21-2022]
- [Post-COVID conditions: information for healthcare providers](#) [07-09-2021]
- [Evaluating and caring for patients with post-COVID conditions: interim guidance](#) [06-14-2021]

UK

- [Long-term effects of coronavirus \(long COVID\)](#) [03-31-2022]

Case Investigation & Contact Tracing

Canada

- [Public health management of cases and contacts associated with COVID-19](#) [02-04-2022]

Ontario

- [COVID-19 integrated testing & case, contact and outbreak management: Omicron surge. Version 3.0 amended March 28, 2022](#) [03-28-2022]
- [COVID-19 fully immunized and previously positive individuals: case, contact and outbreak management interim guidance v 3](#) [10-12-2021]
- [Management of cases and contacts of COVID-19 in Ontario \(version 13.0\)](#) [08-11-2021]
- [Appendix 8: cases with positive COVID-19 serology results and management of cases with multisystem inflammatory syndrome in children \(MIS-C\) temporally associated with COVID-19. Version 2.0](#) [02-18-2021]
- [Appendix 10: case & contact management COVID-19 surge support model \(pilot\)](#) [01-21-2021]

Canadian provinces and territories (other than Ontario)

- BC [Interim guidance: public health management of cases and contacts associated with novel coronavirus \(COVID-19\) in the community](#) [03-16-2022]

WHO

- [Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance](#) [02-17-2022]
- [Considerations for quarantine of contacts of COVID-19 cases](#) [06-25-2021]
- [Operational guide for engaging communities in contact tracing](#) [05-28-2021]
- [Contact tracing in the context of COVID-19](#) [02-01-2021]

CDC

- [Quarantine and isolation](#) [03-30-2022]
- [Contact tracing resources for health departments](#) [03-25-2022]
- [Contact tracer's interview tool: notifying people about an exposure to COVID-19](#) [02-28-2022]
- [Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview](#) [02-28-2021]
- [Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions](#) [02-28-2022]
- [Schools, child care, and colleges](#) [02-07-2022]
- [Contact tracing for COVID-19](#) [02-10-2022]
- [Investigating a COVID-19 case](#) [01-21-2022]
- [Ending home isolation for persons with COVID-19 not in healthcare settings](#) [01-14-2022]
- [COVID-19 contact tracing communications toolkit for health departments](#) [11-05-2021]
- [Global contact tracing](#) [01-15-2021]

UK

- [People with symptoms of a respiratory infection including COVID-19](#) [04-01-2022]
- [COVID-19 rapid guideline: managing COVID-19 NICE guideline](#) [NG191] [03-30-2022]

ECDC

- [Contact tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – 4th update](#) [10-28-2021]
- [Indicator framework to evaluate the public health effectiveness of digital proximity tracing solutions](#) [06-28-2021]

[Back to Top](#)

Infection Prevention and Control

PHAC / Health Canada

- [Federal/provincial/territorial public health response plan for ongoing management of COVID-19](#) [03-31-2022]
- [Coronavirus disease \(COVID-19\): prevention and risks](#) [03-22-2022]
- [Infection prevention and control for COVID-19: interim guidance for outpatient and ambulatory care settings](#) [01-25-2022]
- [Infection prevention and control for COVID-19: interim guidance for home care settings](#) [01-25-2022]
- [Infection prevention and control for COVID-19: interim guidance for acute healthcare settings](#) [01-25-2022]
- [Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance](#) [01-07-2022]
- [Update with consideration of Omicron – interim COVID-19 infection prevention and control in the health care setting when COVID-19 is suspected or confirmed– December 23, 2021](#) [12-24-2021]
- [At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19](#) [12-15-2021]
- [COVID-19 medical masks and N95 respirators: overview](#) [11-29-2021]
- [COVID-19: guidance on indoor ventilation during the pandemic](#) [01-18-2021]

Ontario

- [Infection prevention and control hubs](#) [11-10-2020]

Canadian provinces and territories (other than Ontario)

- QC [COVID-19: evaluation of disinfection options for N95 filtering facepiece respirators in the context of the pandemic](#) [01-13-2022]
- QC [COVID-19: disinfection of N95 single-use filtering facepiece respirators](#) [01-13-2022]
- BC [COVID-19: outbreak management protocol for acute care settings](#) [02-02-2022]

WHO

- [Infection prevention and control in the context of coronavirus disease \(COVID-19\): A living guideline](#) [03-07-2022]
- [Annex to Infection prevention and control during health care when coronavirus disease \(COVID-19\) is suspected or confirmed](#) [10-01-2021]
- [Infection prevention and control during health care when coronavirus disease \(COVID-19\) is suspected or confirmed](#) [07-12-2021]
- [WHO COVID-19 infection prevention and control \(IPC\) pillar achievements. February 2020 – January 2021](#) [05-14-2021]
- [Roadmap to improve and ensure good indoor ventilation in the context of COVID-19](#) [03-01-2021]

CDC

- [Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes](#) [02-02-2022]
- [Considerations for inpatient obstetric healthcare settings](#) [11-19-2021]
- [Cleaning and disinfecting your facility: every day and when someone is sick](#) [11-15-2021]

ECDC

- [Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination](#) [03-29-2021]
- [Infection prevention and control and preparedness for COVID-19 in healthcare settings- sixth update](#) [02-09-2021]
- [Coronavirus disease 2019 \(COVID-19\) and supply of substances of human origin in the EU/EEA - Second update](#) [12-10-2020]
- [Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV](#) [09-24-2020]

UK

- [COVID-19: infection prevention and control \(IPC\)](#) [03-15-2022]
- [Coronavirus \(COVID-19\): safer public places - managing public outdoor settings](#) [02-22-2022]
- [Technical specifications for personal protective equipment \(PPE\)](#) [02-14-2022]
- [COVID-19: guidance for stepdown of infection control precautions and discharging COVID-19 patients from hospital to home settings](#) [01-17-2022]
- [Ventilation of indoor spaces to stop the spread of coronavirus \(COVID-19\)](#) [09-15-2021]

[Back to Top](#)

Section II: Guidelines for Health Sectors

Healthcare Providers

Ontario Ministry of Health

- [COVID-19 interim guidance: Omicron surge management of critical staffing shortages in highest risk settings. Version 3.0](#) [03-31-2022]
- [COVID-19 guidance: acute care v.7](#) [02-16-2022]
- [COVID-19 guidance: primary care providers in a community setting: version 10.0](#) [02-14-2022]
- [COVID-19 guidance: independent health facilities: Version 4](#) [06-19-2020]

Canada

- [COVID-19 pandemic guidance for the health care sector: 4.3 human resources](#) [04-22-2020]

WHO

- [COVID-19 home care bundle for health care workers](#) [02-09-2022]
- [Global pulse survey on continuity of essential health services during the COVID-19 pandemic](#) [02-07-2022]
- [Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic](#) [02-07-2022]
- [Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: Interim guidance](#) [07-07-2021]
- [COVID-19: occupational health and safety for health workers: interim guidance](#) [02-02-2021]

- [Rapid hospital readiness checklist: interim guidance](#) [11-26-2020]

CDC

- [Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2](#) [01-21-2022]
- [Staff shortages](#) [01-21-2022]
- [Operational considerations for the identification of healthcare workers and inpatients with suspected COVID-19 in non-U.S. healthcare settings](#) [01-14-2022]

UK

- [COVID-19: management of staff and exposed patients and residents in health and social care settings](#) [04-01-2022]
- [Contract tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – fourth update](#) [10-28-2021]

[Back to Top](#)

First Responders, Dentistry, Pharmacy, and Allied Health

Ontario Ministry of Health

- [COVID-19 guidance: testing of individuals in pharmacies. Version 2](#) [11-18-2021]
- [Novel coronavirus \(COVID-19\) guidance for paramedic services: version 4](#) [10-01-2020]

PHAC

- [Evidence to support safe return to clinical practice by oral health professionals in Canada during the COVID-19 pandemic: a report prepared for the Office of the Chief Dental Officer of Canada Ontario Ministry of Health](#) [02-02-2022]

WHO

- [Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease \(COVID-19\): interim guidance](#) [02-17-2021]

CDC

- [Evaluation for SARS-CoV-2 testing in animals](#) [updated 03-30-2022]

UK

- [COVID-19: guidance for first responders](#) [03-08-2022]
- [COVID-19: guidance for children's social care services](#) [02-25-2022]
- [COVID-19: guidance for ambulance services](#) [11-30-2021]

Other

- [COVID-19: managing infection risks during in-person dental care](#) Royal College of Dental Surgeons of Ontario [03-11-2022]
- [COVID-19: guidance for the use of teledentistry](#) Royal College of Dental Surgeons of Ontario [no date]

[Back to Top](#)

Death Services

Ontario

- ON [Bereavement Authority of Ontario COVID-19](#) [03-17-2022]

WHO

- [Infection prevention and control for the safe management of a dead body in the context of COVID-19: interim guidance](#) [09-04-2020]

CDC

- [Recommendations for Tribal ceremonies & gatherings](#) [09-30-2021]
- [Collection and submission of postmortem specimens from deceased persons with known or suspected COVID-19: interim guidance](#) [12-02-2020]

UK

- [Handling the deceased with suspected or confirmed COVID-19](#) [04-01-2022]
- [COVID-19: guidance for arranging or attending a funeral or commemorative event](#) [03-22-2022]

Other

- QC [COVID-19: preventive and protective measures for funeral services businesses](#) [07-30-2021]

[Back to Top](#)

Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health

- [COVID-19 screening tool for long-term care homes and retirement homes: version 9](#) [03-18-2022]
- [COVID-19 guidance: long-term care homes and retirement homes for public health units. Version 4](#) [02-03-2022]
- [Retirement homes policy to implement directive #3](#) [12-27-2021]
- [COVID-19 guidance: congregate living for vulnerable populations. Version 2](#) [11-29-2021]
- [COVID-19 guidance: home and community care providers: version 6](#) [05-21-2021]

PHAC

- [Infection prevention and control for COVID-19: interim guidance for long term care homes](#) [01-25-2022]
- [COVID-19: guidance on pets and long-term care homes](#) [07-20-2021]
- [Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes](#) [04-12-2021]
- [COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities](#) [04-14-2020]

WHO

- [Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance](#) [01-08-2021]

CDC

- [How to protect yourself and others](#) [02-25-2022]
- [Interim guidance on management of coronavirus disease 2019 \(covid-19\) in correctional and detention facilities](#) [02-15-2022]
- [Recommendations for quarantine duration in correctional and detention facilities](#) [02-15-2022]
- [Investigating cases in homeless shelters](#) [02-10-2022]

- [Interim guidance on people experiencing unsheltered homelessness](#) [02-10-2022]
- [Interim guidance for SARS-CoV-2 testing in homeless shelters and encampments](#) [02-10-2022]
- [Correctional and detention facilities](#) [02-10-2022]
- [Interim guidance for homeless service providers to plan and respond to Coronavirus Disease 2019 \(COVID-19\)](#) [02-10-2022]
- [Infection control for nursing homes](#) [02-02-2022]
- [Interim guidance for general population disaster shelters during the COVID-19 pandemic](#) [08-30-2021]
- [Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness](#) [04-30-2021]
- [Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings](#) [03-29-2021]

UK

- [Flu and acute respiratory illness in prisons and secure settings: information for staff](#) [updated 04-06-2021]
- [COVID-19: guidance for hostel services for people experiencing homelessness and rough sleeping](#) [updated 04-04-2022]
- [Visiting someone in prison](#) [04-01-2022]
- [COVID-19: admission and care of people in care homes](#) [03-22-2022]
- [Preventing and controlling outbreaks of COVID-19 in prisons and places of detention](#) [03-21-2022]
- [COVID-19: provision of night shelters](#) [03-10-2022]
- [Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, v. 2.1](#) [02-18-2022]
- [COVID-19: how to work safely in domiciliary care in England](#) [01-24-2022]
- [Surveillance of COVID-19 in long-term care facilities in the EU/EEA](#) [11-29-2021]
- [COVID-19: national framework for prison regimes and services](#) [08-18-2021]
- [COVID-19: how to work safely in care homes](#) [08-16-2021]
- [COVID-19 guidance for prison settings v 1.0](#) [07-16-2021]
- [Infection control in prisons and places of detention](#) [07-01-2011]

Canadian provinces and territories (other than Ontario)

- BC [Visitor guidance for long-term care and seniors' assisted living](#) [updated 03-18-2022]
- BC [COVID-19 outbreak management protocol for long-term care and seniors' assisted living settings](#) [02-02-2022]

Other

- CSC [Testing of inmates in federal correctional institutions for COVID-19](#) [updated 04-05-2022]

[Back to Top](#)

Section III: Guidelines for the Community

Travel, Transport & Borders

Ontario Ministry of Health

- [Travelling during COVID-19](#) [03-21-2022]
- [Guidance for public transit agencies and passengers in response to COVID-19](#) [03-21-2022]

Canada

- [Official global travel advisories](#) [updated often]
- [Provincial and territorial restrictions](#) [03-17-2022]
- [COVID-19: exposure notices from select cruise ships](#) [03-11-2022]
- [COVID-19: travel, testing, quarantine and borders](#) [03-08-2022]
- [Guidance material for air operators managing travellers during the check-in procedure for flights departing from an aerodrome in Canada](#) [11-16-2021]
- [Federal safety guidance to protect drivers and limit the spread of COVID-19 in commercial vehicle operations](#) [06-24-2021]

CDC

- [COVID-19 travel recommendations by destination](#) [updated regularly]
- [Stay up to date with your COVID-19 vaccines](#) [updated 04-04-2022]
- [Requirement for proof of COVID-19 vaccination for air passengers](#) [03-03-2022]
- [Public Health Guidance for Potential COVID-19 Exposure Associated with Travel](#) [01-27-2022]
- [Non-U.S. citizen, Non-U.S. immigrants: air travel to the United States](#) [updated 01-27-2022]
- [Requirement for proof of negative COVID-19 test or recovery from COVID-19 for all air passengers arriving in the United States](#) [01-27-2022]
- [Required testing before air travel to the US](#) [01-27-2022]

WHO

- [An implementation guide for the management of COVID-19 on board cargo ships and fishing vessels](#) [12-23-2021]
- [WHO public health checklist for controlling the spread of COVID-19 in ships, sea ports and inland ports](#) [10-00-2021]

UK

- [People with symptoms of a respiratory infection including COVID-19](#) [04-01-2022]
- [Coronavirus \(COVID-19\): advice for heavy goods \(HGV\) and public service vehicle \(PSV\) operators](#) [03-29-2022]
- [Carry out international road haulage](#) [03-18-2022]
- [Travel abroad from England during coronavirus \(COVID-19\)](#) [03-18-2022]
- [Coronavirus \(COVID-19\): cruise ship travel](#) [03-17-2022]
- [Travel to England from another country during coronavirus \(COVID-19\)](#) [03-18-2022]

Other

- [Emergency response plan and action checklist for use by air carriers in the event of a public health emergency](#) [no date]

Schools / Childcare

Ontario Ministry of Health

- [COVID-19: health and safety measures at schools](#) [03-31-2022]
- [COVID-19: health and safety measures for child care](#) [03-31-2022]
- [COVID-19 integrated testing & case, contact and outbreak management interim guidance: Omicron surge](#) [03-28-2022]
- [COVID-19 safety guidelines for: camps](#) [03-01-2022]

PHAC

- [Planning for the 2021-2022 school year in the context of COVID-19 vaccination](#) [02-02-2022]
- [Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance](#) [01-07-2022]
- [COVID-19: organized summer activities for children and youth](#) [12-16-2021]

CDC

- [Considerations for institutions of higher education](#) [02-07-2022]
- [Schools, child care, and colleges](#) [updated 02-07-2022]
- [COVID-19 guidance for operating early care and education/child care programs](#) [01-28-2022]
- [Guidance for COVID-19 prevention in K-12 schools](#) [01-13-2022]

UK

- [Emergency planning and response for education, childcare, and children's social care settings](#) [04-01-2022]
- [Managing coronavirus \(COVID-19\) in education and childcare settings](#) [02-24-2022]

[Back to Top](#)

Mental Health /Addiction /Inequity

Ontario Ministry of Health

- [COVID-19: mental health resources for camp operators version 1.0](#) [07-13-2021]
- [Guidance for consumption and treatment services sites: version 2](#) [04-16-2020]
- [COVID-19 guidance: mental health and addictions service providers in community settings: version 2](#) [09-24-2020]

PHAC

- [Helping people who use substances during the COVID-19 pandemic](#) [07-06-2021]

Provinces & Territories (excluding Ontario)

- BC [COVID-19: harm reduction and overdose response](#) [01-07-2022]
- AB [Harm reduction and COVID-19: guidance document for community service providers](#) [12-08-2020]
- QC [COVID-19: tackling social isolation and loneliness among seniors in a pandemic context](#) [10-28-2020]
- BC [COVID-19: provincial episodic overdose prevention service \(e-OPS\) protocol](#) [06-26-2020]

WHO

- [Mental health and COVID-19: Early evidence of the pandemic's impact: Scientific brief, 2 March 2022](#) [03-02-2022]
- [Rise, respond, recover: renewing progress on women's, children's and adolescent's health in the era of COVID-19](#) [12-00-2021]
- [Social isolation and loneliness among older people: advocacy brief](#) [07-29-2021]
- [Smoking and COVID-19](#) [06-30-2020]
- [Addressing violence against children, women and older people during the COVID-19 pandemic: key actions](#) [06-18-2020]
- [COVID-19 and violence against women: what the health sector / system can do](#) [04-07-2020]

CDC / SAMHSA

- [Substance abuse and mental health training and technical assistance related to COVID-19](#) [08-16-2021]
- [Virtual recovery resources](#) [07-00-21]
- [Disaster planning handbook for behavioural health service programs](#) [03-00-2021]
- [Interim guidance for syringe services programs](#) [05-15-2020]
- [Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020](#) [05-07-2020]
- [Considerations for crisis centers and clinicians in managing the treatment of alcohol or benzodiazepine withdrawal during the COVID-19 epidemic: March 19, 2020](#) [03-19-2020]
- [Intimate partner violence and child abuse considerations during COVID-19](#) [no date]

UK

- [Alcohol and drug misuse prevention and treatment guidance](#) [03-07-2022]
- [Every Mind Matters: looking after your mental health](#) [no date]
- [Domestic abuse: how to get help](#) [11-11-2021]

Other

- [Public health ethics and COVID-19: selected resources](#) [11-00-2021]
- [Risk mitigation in the context of dual public health emergencies. Version 1.5](#) [03-00-20]

[Back to Top](#)

Community

Ontario Ministry of Health

- [COVID-19 public health measures and advice](#) [03-21-2022]
- [Guidance on community emergency evacuations: version 2](#) [07-06-2021]

PHAC

- [Individual and community-based measures to mitigate the spread of coronavirus disease \(COVID-19\) in Canada](#) [02-02-2022]
- [COVID-19: organized summer activities for children and youth](#) [12-16-2021]
- [At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19](#) [12-15-2021]

WHO

- [Key planning recommendations for mass gatherings in the context of COVID-19](#) [11-04-2021]

CDC

- [Information about COVID-19, pets, and other animals](#) [03-31-2022]
- [Operational considerations for community isolation centers](#) [updated 03-30-2022]
- [Breastfeeding & caring for newborns](#) [01-20-2022]
- [Interim guidance for general population disaster shelters during the COVID-19 pandemic](#) [08-04-2021]
- [COVID-19 response health equity strategy: accelerating progress towards reducing COVID-19 disparities and achieving health equity](#) [08-21-2020]
- [Considerations for owners and operators of multifamily housing including populations at increased risk for complications from COVID-19](#) [05-05-2021]

UK

- [COVID-19: guidance for providers of accommodation for asylum seekers](#) [updated 04-04-2022]
- [Using the NHS COVID Pass to demonstrate COVID-19 status](#) [updated 04-01-2022]
- [Living safely with respiratory infections, including COVID-19](#) [updated 04-01-2022]
- [Supported living services during coronavirus \(COVID-19\)](#) [03-04-2022]
- [COVID-19: guidance for the safe use of places of worship](#) [02-25-2022]

Australia

- [Early aero-medical evacuation of COVID-19 cases and contacts from remote communities](#) [08-20-2020]

[Back to Top](#)

Businesses/Workplaces

Ontario Ministry of Health

- [COVID-19 and workplace health and safety](#) [03-28-2022]
- [COVID-19 customer screening](#) [03-21-2022]
- [COVID-19 worker and employee screening](#) [03-21-2022]
- [Restaurant and food services health and safety during COVID-19](#) [01-31-2022]
- [COVID-19 guidance: workplace outbreaks v2.0](#) [10-05-2021]
- [Guidance for employers managing workers with symptoms within 48 hours of COVID-19 immunization](#) [11-30-2021]

WHO

- [Preventing and mitigating COVID-19 at work](#) [05-19-2021]

CDC

- [Workplaces & businesses: plan, prepare and respond](#) [10-18-2021]
- [Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace](#) [08-13-2021]

ECDC

- [Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern](#) [02-07-2022]

UK

- [Reducing the spread of respiratory infections, including COVID-19, in the workplace](#) [04-04-2022]
- [COVID-19: providing unpaid care](#) [02-15-2022]

Other

- BC [Guidance for outside dining spaces based on the Provincial Health Officer's order to food and liquor serving premises](#) [04-23-2021]

[Back to Top](#)

Masks (Non-Medical)

Ontario Ministry of Health

- [Face coverings and face masks](#) [03-21-2021]

PHAC

- [COVID-19 mask use: advice for community settings](#) [02-01-2022]

WHO

- [What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control?](#) [00-00-2021]
- [Mask use in the context of COVID-19](#) [12-01-2020]

CDC

- [Your guide to masks](#) [02-25-2022]
- [Use of masks to help slow the spread of COVID-19](#) [08-12-2021]

ECDC

- [Using face masks in the community: first update – effectiveness in reducing transmission of COVID-19](#) [02-07-2022]
- [Use of gloves in healthcare and non-healthcare settings in the context of the COVID-19 pandemic](#) [07-02-2020]

UK

- [Face coverings: when to wear one, exemptions, and how to make one](#) [01-27-2022]
- [The Disabled Persons Transport Advisory Committee \(DPTAC\) position on face coverings](#) [03-22-2021]

Other

- BC [Face coverings \(COVID-19\)](#) [12-03-2021]